Trials / Completed
CompletedNCT01253603
Efficacy, Safety, and Pharmacokinetics of QAW039
A Randomized, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety, and Pharmacokinetics of QAW039 in Steroid-free Patients With Mild to Moderate Persistent Asthma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 170 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess the safety, efficacy and pharmacokinetics of QAW039 in steroid-free patients with mild to moderate persistent asthma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | QAW039 capsules once daily for 28 days | |
| DRUG | Placebo to QAW039 capsules once daily for 28 days | |
| DRUG | Fluticasone propionate inhaler twice daily for 28 days |
Timeline
- Start date
- 2010-11-01
- Primary completion
- 2011-09-01
- Completion
- 2011-09-01
- First posted
- 2010-12-03
- Last updated
- 2020-12-19
Locations
26 sites across 5 countries: United States, Belgium, Germany, Romania, South Korea
Source: ClinicalTrials.gov record NCT01253603. Inclusion in this directory is not an endorsement.